secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001655759-24-000043
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas licenses ARV-766 to Novartis for $150M upfront; up to $1.01B in milestones
--------------------------------------------------------------------------------

- Arvinas grants Novartis exclusive worldwide license to develop and commercialize ARV-766 for prostate cancer.
- Novartis pays $150M upfront; Arvinas eligible for up to $1.01B in development, regulatory, and commercial milestones plus tiered royalties.
- Asset purchase includes Arvinas' preclinical AR-V7 program sold to Novartis.
- Novartis assumes full responsibility for global clinical development and commercialization of ARV-766.
- Closing subject to HSR antitrust waiting period expiration or termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/0001655759-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/arvn-20240410.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer